Page 3 - Mark Mintun News Today

Brits should be able to get the new Alzheimers drug donanemab which can slow the disease to a crawl in the next two years with experts urging regulators to do all they can to approve the treatment.

A breakthrough - donanemab has emerged as a significant milestone in the battle against Alzheimer's after a global trial confirmed its ability to slow down cognitive decline. Made by US pharmaceuticals group Eli Lilly, the results of a clinical trial to showcase the findings said antibody treatment slowed progression by about 35 per cent in the early stages of the disease, allowing people with Alzheimer’s to continue performing day-to-day tasks such as shopping, housekeeping, managing the...

A new drug has been hailed as a "turning point in the fight against Alzheimers" after it was found to slow the progression of the…

New research shows another experimental Alzheimers drug can modestly slow patients inevitable worsening. Patients given monthly infusions of Eli Lilly and Co.s donanemab declined about four to seven months more

WASHINGTON (AP) — Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.

An Alzheimer’s drug that attacks the protein amyloid does not work as well in people with more advanced disease

Some public health experts worry the FDA has set impossible standards for menthol vapes.

Participants were able to stop treatment after achieving amyloid plaque clearance and experience lasting results.

A landmark trial has shown that a drug called donanemab has significantly halted brain deterioration - only the second drug ever proven to do so - in a breakthrough for Alzheimer's research

A new drug has been found to slow the progression of Alzheimer's, with experts hailing it as a turning point in the fight against the disease.